Subcutaneous mepolizumab in children aged 6 to 11 years with severe eosinophilic asthma
Sign Up to like & getrecommendations! Published in 2019 at "Pediatric Pulmonology"
DOI: 10.1002/ppul.24508
Abstract: There are no published reports for anti‐interleukin‐5 therapy in children read more here.
Keywords: children aged; severe eosinophilic; mepolizumab children; eosinophilic asthma ... See more keywords
Mepolizumab and Benralizumab in Severe Eosinophilic Asthma: Preliminary Results of a Proteomic Study
Sign Up to like & getrecommendations! Published in 2020 at "Lung"
DOI: 10.1007/s00408-020-00379-6
Abstract: Benralizumab and mepolizumab are new therapies for severe eosinophilic asthma. They are both humanized IgG antibodies, targeting the IL‐5 receptor and IL‐5, respectively, suppressing the corresponding pathways. No specific biomarkers have been proposed to evaluate… read more here.
Keywords: eosinophilic asthma; mepolizumab benralizumab; severe eosinophilic; proteomic study ... See more keywords
Synergistic activation of pro-inflammatory type-2 CD8+ T lymphocytes by lipid mediators in severe eosinophilic asthma
Sign Up to like & getrecommendations! Published in 2018 at "Mucosal Immunology"
DOI: 10.1038/s41385-018-0049-9
Abstract: Human type-2 CD8+ T cells are a cell population with potentially important roles in allergic disease. We investigated this in the context of severe asthma with persistent airway eosinophilia—a phenotype associated with high exacerbation risk… read more here.
Keywords: eosinophilic asthma; pro inflammatory; severe eosinophilic; type cd8 ... See more keywords
Effectiveness of mepolizumab in patients with severe eosinophilic asthma: results from real-world clinical practice in Finland
Sign Up to like & getrecommendations! Published in 2022 at "Journal of Asthma"
DOI: 10.1080/02770903.2021.2020813
Abstract: Abstract Objectives Mepolizumab treatment provides clinical benefits for patients with severe eosinophilic asthma in randomized controlled trials. However, real-world data for patients in Finland are lacking. Methods This retrospective, non-interventional, chart review study included patients… read more here.
Keywords: eosinophilic asthma; asthma; patients severe; severe eosinophilic ... See more keywords
Biological therapies for eosinophilic asthma
Sign Up to like & getrecommendations! Published in 2018 at "Expert Opinion on Biological Therapy"
DOI: 10.1080/14712598.2018.1492540
Abstract: ABSTRACT Introduction: Severe uncontrolled asthma is by definition refractory to traditional therapies or can be controlled only with therapies that have intolerable side effects. Monoclonal antibodies that target interleukin (IL)-5/IL-5Rα, IgE, and IL-4Rα have shown… read more here.
Keywords: severe eosinophilic; therapies eosinophilic; eosinophilic asthma; clinical trials ... See more keywords
Regulatory T cell monitoring in severe eosinophilic asthma patients treated with mepolizumab
Sign Up to like & getrecommendations! Published in 2021 at "Scandinavian Journal of Immunology"
DOI: 10.1111/sji.13031
Abstract: Severe eosinophilic asthma (SEA) has been associated with T‐helper type 2 (Th2) inflammatory response. A good understanding of T cell functions in asthma is important for therapy, especially in the choice of biological treatments for… read more here.
Keywords: severe eosinophilic; eosinophilic asthma; asthma; treated mepolizumab ... See more keywords
Real-life effects of benralizumab on airway oscillometry in severe eosinophilic asthma
Sign Up to like & getrecommendations! Published in 2023 at "BMJ Open Respiratory Research"
DOI: 10.1136/bmjresp-2022-001472
Abstract: Introduction Eosinophil depletion with benralizumab reduces exacerbations and improves disease control and FEV1 in patients with severe eosinophilic asthma. However, few studies have investigated the effect of biologics on small airways dysfunction (SAD) even though… read more here.
Keywords: eosinophilic asthma; real life; asthma; oscillometry ... See more keywords
P71 Mepolizumab in adolescents with severe eosinophilic asthma not eligible for omalizumab: one centre’s experience
Sign Up to like & getrecommendations! Published in 2017 at "Thorax"
DOI: 10.1136/thoraxjnl-2017-210983.213
Abstract: Introduction Mepolizumab is an anti-interleukin-5 monoclonal antibody shown to reduce asthma exacerbations in adults and adolescents with severe eosinophilic asthma.1 The Scottish Medicines Commission has accepted it for restricted use in adults as an add-on… read more here.
Keywords: asthma eligible; severe eosinophilic; mepolizumab; eosinophilic asthma ... See more keywords
Personalized Approach of Severe Eosinophilic Asthma Patients Treated with Mepolizumab and Benralizumab
Sign Up to like & getrecommendations! Published in 2020 at "International Archives of Allergy and Immunology"
DOI: 10.1159/000508936
Abstract: Background: New anti-IL-5 antibodies, mepolizumab and benralizumab, have recently been approved for severe asthma, sharing the same inclusion criteria. Objective: To contribute on biomarkers research leading to the personalized choice, we investigated L-selectin, Krebs von… read more here.
Keywords: mepolizumab benralizumab; severe eosinophilic; personalized approach; patients treated ... See more keywords
Improvement in rhinosinusitis health related quality of life in patients with severe eosinophilic asthma
Sign Up to like & getrecommendations! Published in 2017 at "European Respiratory Journal"
DOI: 10.1183/1393003.congress-2017.pa3583
Abstract: Rationale: Patients with Severe Eosinophilic Asthma (SEA) frequently have comorbid nasal polyps (NP). Treatment with mepolizumab may improve NP impact on health-related quality of life (HRQOL). Methods: MUSCA was a Phase IIIb, placebo-controlled, double-blind, parallel-group,… read more here.
Keywords: patients severe; severe eosinophilic; health related; eosinophilic asthma ... See more keywords
Suboptimal treatment response to anti-IL-5 monoclonal antibodies in severe eosinophilic asthmatics with airway autoimmune phenomena
Sign Up to like & getrecommendations! Published in 2020 at "European Respiratory Journal"
DOI: 10.1183/13993003.00117-2020
Abstract: Background In clinical trials, the two anti-interleukin (IL)-5 monoclonal antibodies (mAbs: mepolizumab and reslizumab) approved to treat severe eosinophilic asthma reduce exacerbations by ∼50–60%. Objective To observe response to anti-IL-5 mAbs in a real-life clinical… read more here.
Keywords: suboptimal response; severe eosinophilic; response; sputum ... See more keywords